MDS

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS.

With my myelodysplastic syndrome and age, I find it hard to keep up; however, cancer and fatigue have taught me to live at my own pace.

While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, researchers urged.

An expert explained the burden that red blood cell transfusions can place on patients with MDS.

Having myelodysplastic syndromes has taught me to cherish every day and to pursue the things that matter to me, like publishing a book I’ve been writing.

Keri is also a true partner in the management and care of the whole patient.

Cancer has changed my self-image, but I’ve learned a few tricks to help boost my self-confidence.

Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease.

Just like athletes in the Olympics, it's important for cancer survivors to keep track of everything they feel and to know their bodies well.

The National Comprehensive Cancer Network now recommends Rytelo for patients with myelodysplastic syndrome who require blood transfusions.

Post-transplant cyclophosphamide decreased the risk of complications in patients with blood cancers who underwent a stem cell transplant from an unrelated donor.

Although MDS didn’t leave physical scars, the invisible ones, like side effects from treatment, are ones that linger.

For patients with MDS who benefit from delaying transplants, it’s important to take care of their health while savoring their time before transplant.

From Don Omar announcing being cancer free to “General Hospital” star John York talking about treatment for his two cancers, here’s what’s going on in the oncology space this week.

As a cancer survivor, I realize that life doesn’t always go the way we think it will, but it doesn’t erase the guilt.

Approximately half of the patients with MDS who responded to treatment with Rytelo went a year without needing a blood transfusion, one expert explained.

The Food and Drug Administration has approved Rytelo to treat certain patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia.

Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl.

The safety profile of 200 milligrams and 300 milligrams of oral Ongureg were similar in patients with lower- to intermediate-risk MDS.

I’ve experienced mixed emotions during my periods of remission for my myelodysplastic syndrome.

As a cancer survivor, I’m pleading for more research on cancer related fatigue.

I must admit when people call us cancer survivors "strong," it's a double-edged sword.

Receiving early transfusions and treatment to reduce transfusion dependency significantly improves survival and quality of life in low-risk MDS.

I was surprised that COVID-19 taught me how to cope with the daily annoyances of cancer.

The novel treatment elritercept received a Fast Track designation from the FDA to treat anemia in patients with MDS.

Patients taking Tibsovo to treat MDS or AML may want to discuss the appropriate medications to treat and prevent infections, an expert said.

The Oncologic Drug Advisory Committee voted that the benefits of imetelstat outweigh the risks for transfusion-dependent myelodysplastic syndrome and anemia.

Attending follow-up appointments as blood cancer survivors can help prevent more dangerous outcomes, including secondary cancers, an expert told CURE®.

The first patient has been enrolled in a clinical trial evaluating a reduced dose of post-transplant immunosuppressive chemotherapy cyclophosphamide for patients with blood cancers.

Orca-T outperformed post-transplant cyclophosphamide when it came to relapse-free survival and overall survival in patients with blood cancer who underwent a stem cell transplantation from a matched unrelated donor.